E
CTMX icon

Ergoteles’s CytomX Therapeutics CTMX Stock Holding History

Ergoteles’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-279,056
Closed -$405K – 1528
2022
Q3 		$405K Sell
279,056
-38,944
-12% -$59.9K 0.01% 841
2022
Q2 		$582K Buy
+318,000
New +$609K 0.02% 773

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ergoteles's CTMX Position: Q4 2022 in Review

Ergoteles sold out of CytomX Therapeutics (CTMX) in Q4 2022, closing a stake of 279,056 shares — an estimated $405K sold.

Ergoteles first reported a position in CTMX in Q2 2022 and held it in 2 quarters. The position peaked at $582K in Q2 2022. 81 funds tracked by Wall St. Rank hold CTMX as of Q4 2022.

  • Ergoteles reported no remaining CytomX Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 279,056 CytomX Therapeutics shares in Q4 2022, an estimated $405K.
  • Ergoteles first reported a position in CytomX Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ergoteles's CytomX Therapeutics position peaked at $582K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.